ALLMedicine™ Cirrhosis Center

Jun 26th, 2022 - BACKGROUND Necrotizing fasciitis is a life-threatening infection of the deep soft tissues that leads to progressive destruction of the fascia and subcutaneous fat. It typically spreads along the muscle fascia planes because of the relatively poor ...

Jun 25th, 2022 - Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and emerging as the leading cause of liver cirrhosis, liver transplantation and hepatocellular carcinoma (HCC). NAFLD is a metabolic disease and considered the he...

Jun 25th, 2022 - Hepatitis B virus (HBV) infection is the leading cause of liver-related death worldwide, particularly in Asia. Patients with either current or past HBV infection are at risk of cirrhosis and hepatocellular carcinoma (HCC). Here, we investigated th...

Jun 25th, 2022 - Cirrhosis-related complications are a major burden. Rifaximin soluble solid dispersion (SSD) tablets (immediate-release [IR]; sustained extended-release [SER]) were designed to increase rifaximin water solubility. These analyses evaluate dosing fo...

Jun 25th, 2022 - The majority of Australia's hepatitis B virus (HBV) burden is borne by culturally and linguistically diverse (CALD) populations, and antiviral treatment is the mainstay of intervention. Using modelling, we estimated the impact of targeted antivira...

Jun 7th, 2022 - Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropa...

May 16th, 2022 - To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other...

Mar 19th, 2022 - The prevention and management of bleeding and thrombosis in patients with cirrhosis poses several difficult clinical questions. These Clinical Practice Guidelines have been developed to provide practical guidance on debated topics, including curre...

Sep 29th, 2021 - AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.|2021|O'Shea RS,Davitkov P,Ko CW,Rajasekhar A,Su GL,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemical...

Sep 29th, 2021 - AGA Technical Review on Coagulation in Cirrhosis.|2021|Intagliata NM,Davitkov P,Allen AM,Falck-Ytter YT,Stine JG,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemically induced,blood,diagnosis,drug therapy,

Jun 24th, 2022 - We intend to enroll up to 350 subjects with chronic hepatitis C virus (HCV) infection. Subjects will be recruited from two sources: Phase I: treatment naive or experienced who have failed a prior treatment (including DAA-experienced) who are willi...

Jun 24th, 2022 - Hepatitis E virus infection commonly presents as an acute self-limiting hepatitis in the developing world. However there have been reports that chronic hepatitis E may develop in immunocompromised subjects such as renal and liver transplant recipi...

Jun 24th, 2022 - Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the syst...

Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Jun 24th, 2022 - At present, there are no clear guidelines as to when antiretroviral therapy for human immunodeficiency virus (HIV) infection should be stopped in the setting of elevated liver enzymes. In large part, this is due to a limited understanding of the n...

Jun 24th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the.

Jun 23rd, 2022 - Key clinical point: Nivolumab may serve as a first-line systemic treatment option in patients with hepatocellular carcinoma (HCC) and Child-Pugh B (CP-B) cirrhosis. Major finding: Patients receiving nivolumab vs.

Jun 22nd, 2022 - NEW YORK (Reuters Health) - Alcohol-associated liver disease is now the most common indication for liver transplant wait-listing among young American adults, researchers say. From 2003 to 2018, the diagnosis of alcoholic liver disease (ALD) as an ...

Jun 7th, 2022 - The Diagnosis: Cutaneous Amyloidosis A punch biopsy confirmed the diagnosis of cutaneous amyloidosis, which is characterized by the deposition of amyloid proteins in the skin without systemic involvement. Subtypes of cutaneous amyloidosis include.

Jun 7th, 2022 - CHICAGO – In a large case series of metastatic breast cancer patients with pseudocirrhosis, researchers found that almost all such patients had hormone receptor–positive (HR+) disease as well as extensive liver metastases. Pseudocirrhosis appears.